Ingevity (NGVT) As Portfolio Repositioning Fuels An Undervalued Narrative

Ingevity (NGVT) is scheduled to present at the Jefferies Global Industrials Conference on 10 September 2026 in New York, providing investors with updated commentary on its chemicals, carbon products, and polymer operations.

Ingevity's share price has risen to US$69.41 after a 1-day share price return of 3.40%. However, the 30-day share price return is down 8.90% and the 90-day share price return is down 3.57%. At the same time, the year-to-date share price return of 15.51% and 1-year total shareholder return of 19.36% suggest that momentum over the past year has been positive despite recent softness.

Spot opportunities around Ingevity by scanning a curated set of resilient materials and industrials stocks in the 11 resilient stocks with low risk scores.

After a strong run over the past year but a weaker stretch in recent weeks, Ingevity now asks a simple question of investors: Does the current valuation still leave enough upside to justify the risk?

Most Popular Narrative: 22% Undervalued

On the most followed narrative, Ingevity's fair value sits at $89 against a last close of $69.41, which sets up a sizable valuation gap for investors to assess.

Accelerated portfolio repositioning and the advanced-stage divestiture of non-core, lower-margin businesses (Industrial Specialties and CTO refinery) are expected to drive a step-change in margin profile, enabling greater focus and capital allocation toward higher-growth, value-added specialty chemicals, supporting both revenue quality and sustained EBITDA margin improvement.

Read the complete narrative.

Curious what kind of margin profile justifies that higher valuation for Ingevity. The narrative leans heavily on future earnings power and a sharply different profit mix. The key assumptions pull together revenue resilience, richer product economics, and a tighter share count.

Result: Fair Value of $89 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

Still, the Ingevity narrative hinges on APT recovering from recent goodwill impairment and margin pressure, while tariff and trade uncertainty continue to threaten demand in key end markets.

Find out about the key risks to this Ingevity narrative.

Another View on Ingevity’s Valuation

The first narrative leans on cash flows and long term earnings power to argue Ingevity is 22% undervalued at a fair value of $89 per share. A second lens using earnings multiples tells a very different story for anyone watching entry price closely.

On current numbers, Ingevity trades on a P/E of 94.7x, while the estimated fair ratio is 33.6x. The wider market is far lower, with the US Chemicals industry at 24.2x and peers at 26.2x. That gap suggests the stock carries meaningful valuation risk if expectations reset closer to those reference points. The open question is which signal you trust more.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Mixed messages on Ingevity so far. If you want to move quickly and evaluate the balance of concerns versus optimism for yourself, start by reviewing the 4 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Ingevity?

If Ingevity has your attention, do not stop here. Broaden your watchlist now with fresh ideas that match your risk tolerance and return expectations.

• Target potential mispricing by hunting for quality companies trading below estimated value through the 31 high quality undervalued stocks.
• Strengthen the income side of your portfolio by reviewing companies in the 6 dividend fortresses that offer higher yields with supporting fundamentals.
• Protect your capital by focusing on sturdier balance sheets using the list of solid balance sheet and fundamentals (23 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com